Oppenheimer Asset Management’s Momenta Pharmaceuticals, Inc. MNTA Stock Holding History

Oppenheimer Asset Management’s Portfolio MNTA Stock Details MNTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-50	Closed	-$1K	–	1522
2020 Q1	$1K	Hold	50	–	–	﹤0.01%	1492
2019 Q4	$1K	Hold	50	–	–	﹤0.01%	1593
2019 Q3	$1K	Sell	50 -25	-33%	-$302	﹤0.01%	1596
2019 Q2	$1K	Sell	75 -13	-15%	-$173	﹤0.01%	1615
2019 Q1	$1K	Sell	88 -72	-45%	-$920	﹤0.01%	1591
2018 Q4	$2K	Sell	160 -12,159	-99%	-$169K	﹤0.01%	1601
2018 Q3	$324K	Sell	12,319 -848	-6%	-$22.9K	0.01%	941
2018 Q2	$269K	Sell	13,167 -653	-5%	-$14K	0.01%	975
2018 Q1	$251K	Sell	13,820 -12,838	-48%	-$214K	0.01%	990
2017 Q4	$493K	Hold	26,658	–	–	0.01%	795
2017 Q3	$493K	Sell	26,658 -297	-1%	-$4.96K	0.01%	799
2017 Q2	$456K	Sell	26,955 -1,268	-4%	-$19.3K	0.01%	804
2017 Q1	$377K	Buy	+28,223	New	+$442K	0.01%	859

Other funds holding MNTA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Oppenheimer Asset Management's MNTA Position: Q2 2020 in Review

Oppenheimer Asset Management sold out of Momenta Pharmaceuticals, Inc. (MNTA) in Q2 2020, closing a stake of 50 shares — an estimated $1K sold.

Oppenheimer Asset Management first reported a position in MNTA in Q1 2017 and held it in 13 quarters. The position peaked at $493K in Q4 2017. 237 funds tracked by Wall St. Rank hold MNTA as of Q2 2020.

Oppenheimer Asset Management reported no remaining Momenta Pharmaceuticals, Inc. position as of Q2 2020 after selling out during the quarter.
Oppenheimer Asset Management sold 50 Momenta Pharmaceuticals, Inc. shares in Q2 2020, an estimated $1K.
Oppenheimer Asset Management first reported a position in Momenta Pharmaceuticals, Inc. in Q1 2017 and held it in 13 quarters.
Oppenheimer Asset Management's Momenta Pharmaceuticals, Inc. position peaked at $493K in Q4 2017.
237 funds tracked by Wall St. Rank held Momenta Pharmaceuticals, Inc. as of Q2 2020.

Based on Oppenheimer Asset Management's 13F filing for Q2 2020, filed 11 Aug 2020.